Clinical Trial Next for Laser Technique
!%Carl Zeiss Meditec AG%! of Dublin, Calif., and Jena, Germany, has received conditional approval from the FDA to initiate a clinical trial for its ReLEx smile procedure to correct myopia. The technique for refractive surgery combines femtosecond laser technology and precise lenticule extraction for minimally invasive laser vision correction in a single system, the VisuMax femtosecond laser. In lasik procedures, the excimer laser vaporizes tissue, while the ReLEx smile method generates a refractive lenticule in the intact cornea with the femtosecond laser. The surgeon then removes the lenticule through a small incision without having to move the patient to an excimer laser.
LATEST NEWS
- Fraunhofer CAP Appoints Head, Scientific Director: People in the News: 1/15/25
Jan 15, 2025
- Bioluminescent Tags Track RNA Dynamics in Live Cells in Real Time
Jan 15, 2025
- Sensing and Inspection Specialist EVK Joins Headwall Group
Jan 14, 2025
- PHOTON IP Raises $4.9M Seed Round
Jan 14, 2025
- Graphene Prevents Damage to Flexible Thin Films for Wearable Electronics
Jan 14, 2025
- Thorlabs Acquires VCSEL Developer, Longtime Partner Praevium Research
Jan 13, 2025
- Photoactivated Gel Achieves Bone Regeneration and Adhesion at Same Time
Jan 13, 2025
- Electrically-Pumped GaAs-Based Nano-Ridge Lasers Fabricated at Wafer Scale
Jan 13, 2025